Printer Friendly

ISIS PHARMACEUTICALS PROMOTES CHRISTOPHER MIRABELLI AND B. LYNNE PARSHALL

 CARLSBAD, Calif., Feb. 10 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) today announced the promotions of Christopher K. Mirabelli, Ph.D., and B. Lynne Parshall, Esq.
 Dr. Mirabelli, age 38, has been promoted to Executive Vice President of Research and Preclinical Development from Senior Vice President of Research and Preclinical Development. Dr. Mirabelli, a co-founder of the Company, is responsible for advancing fundamental research and identifying compounds for clinical development. Dr. Mirabelli has a broad range of drug discovery and preclinical development experience in infectious diseases, cancer, autoimmune diseases, and inflammatory disease. Dr. Mirabelli is an author of 13 patents, and has published more than 200 scientific papers and abstracts in both biological and chemical journals. Dr. Mirabelli was formerly Director of Molecular Pharmacology at SmithKline & French. He also was an adjunct assistant professor in the Pharmacology Department of the University of Pennsylvania from 1984-1990. Dr. Mirabelli received his Ph.D. in Pharmacology in 1981 from Baylor College of Medicine. Dr. Mirabelli reports to Stanley T. Crooke, M.D., Ph.D., who is Chairman, President, and CEO of Isis Pharmaceuticals.
 Ms. Parshall, age 38, has been promoted to the position of Senior Vice President and General Counsel, with responsibility for business development, legal affairs and administration. In this position, Ms. Parshall will report to Daniel L. Kisner, COO. She retains her title as Secretary of the Isis Board of Directors. Most recently, Ms. Parshall was a Partner with the firm of Cooley Godward Castro Huddleson and Tatum. Ms. Parshall joined Isis in November 1991 as Vice President and Secretary of its Board of Directors. Ms. Parshall has also served as Vice President of Business Development of Biotrade, Inc., a medical device company, during 1988 and 1989. Ms. Parshall received her J.D. at Stanford Law School in 1979 and her B.A. from Harvard University in 1976. Ms. Parshall is a member of the American, California, Santa Clara County and San Diego, North County Bar Associations and a member of the Licensing Executives Society.
 "Dr. Mirabelli and Ms. Parshall have played crucial roles in the success of Isis. It is my personal pleasure to acknowledge their contributions. These promotions enable each to take important new steps in the evolution of their careers," said Dr. Stanley T. Crooke.
 Isis Pharmaceuticals, based in Northern San Diego County, is engaged in the discovery, development and marketing of novel therapeutic products based in proprietary oligonucleotides. Isis has a broad oligonucleotides research program and its first oligonucleotide based drug, ISIS 2105, is in Phase II clinical trials.
 -0- 2/10/92
 /CONTACT: Stanley T. Crooke, M.D., Ph.D., or Patricia Lowenstam of Isis Pharmaceuticals, 619-931-9200, or Anthony J. Russo, Ph.D., of Noonan-Russo Communications, 212-979-9180, for Isis Pharmaceuticals/
 (ISIP)


CO: Isis Pharmaceuticals, Inc., ST: California IN: MTC SU: PER

LD-TM -- NY009 -- 4992 02/10/93 08:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1993
Words:473
Previous Article:JUST TOYS REPORTS RECORD SALES AND EARNINGS
Next Article:TOSCO REPORTS RESULTS
Topics:


Related Articles
ISIS PHARMACEUTICALS OBTAINS LICENSE TO LIPID FORMULATIONS TECHNOLOGY FROM VICAL
ISIS PHARMACEUTICALS ANNOUNCES ISSUANCE OF ANTISENSE PATENT
ISIS PHARMACEUTICALS AND EISAI AGREE TO CODEVELOP ANTISENSE DRUG
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS SIGN FINAL AGREEMENT TO FORM PERISIS
ISIS REPORTS CONTINUING TREND OF LOWER LOSSES FOR THE THIRD QUARTER OF 1993
Isis Receives Eleven Patents for Discoveries in Antisense and Combinatorial Chemistry
Isis Acquires Antisense Patent and Technology Estate from Gilead Sciences.
Isis Pharmaceuticals Announces Election of B. Lynne Parshall To Board of Directors.
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters